Buchumschlag

In response: Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Azael Freites‐Martinez, Zoe Apalla, Vincent Sibaud
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Journal of the European Academy of Dermatology and Venereology
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Rifampicin and clindamycin for epidermal growth factor receptor inhibitor‐related acneiform rash
von: Giovanni Paolino, et al.
Veröffentlicht: (2025)

Dermatologic immune‐related adverse events: It is time for a game change!
von: Davide Fattore, et al.
Veröffentlicht: (2024)

Nail toxicities associated with cancer therapies: Insights and recommendations from the EADV task force dermatology for cancer patients
von: Matilde Iorizzo, et al.
Veröffentlicht: (2025)

Prevention and management of cutaneous immune‐related adverse events: EADV Task Force statement
von: Davide Fattore, et al.
Veröffentlicht: (2025)

Expert consensus for prevention, diagnosis and management of persistent chemotherapy‐induced alopecia
von: Azael Freites‐Martinez, et al.
Veröffentlicht: (2025)

Dupilumab for immune checkpoint inhibitors‐induced pruritic dermatoses: A retrospective, multicentric study
von: Damien Giacchero, et al.
Veröffentlicht: (2025)

Leg ulcers associated with tyrosine kinase inhibitors of vascular endothelial growth factor receptors
von: Lykimheng Lor, et al.
Veröffentlicht: (2025)

Supportive oncodermatology is the key!
von: E. Parriel, et al.
Veröffentlicht: (2024)

Advanced age and dermoscopic streaks increase the likelihood of a diagnostic upgrade of ambiguous melanocytic tumours after clinicopathological correlation
von: Emmanouil Chousakos, et al.
Veröffentlicht: (2024)

Reply to “Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa”
von: Fabrizio Martora, et al.
Veröffentlicht: (2024)

Management of folliculitis decalvans: The EADV task force on hair diseases position statement
von: Anna Waśkiel‐Burnat, et al.
Veröffentlicht: (2025)

The immune ensemble behind mogamulizumab‐associated rash
von: Oleg E. Akilov
Veröffentlicht: (2026)

Dermatologic adverse events associated with amivantamab: A multicentre study
von: Vasiliki Nikolaou, et al.
Veröffentlicht: (2026)

Systemic treatment of immune checkpoint inhibitor‐induced psoriasis: Inference‐based guidance
von: Kim A. Papp, et al.
Veröffentlicht: (2025)

Management of classic lichen planopilaris: The EADV task force on hair diseases position statement
von: Seyed Morteza Seyed Jafari, et al.
Veröffentlicht: (2026)

Sequelae of epidermal necrolysis: Patients are still in demand years later
von: Audrey Colin, et al.
Veröffentlicht: (2025)

Macrophages and plasmocytoid dendritic cells are recruited to the epidermis during epidermal necrolysis
von: Ines Saizonou, et al.
Veröffentlicht: (2025)

Prevalence and predictors of posttraumatic stress disorder in Stevens Johnson syndrome and toxic epidermal necrolysis
von: T. J. Stewart, et al.
Veröffentlicht: (2025)

Beyond the scoreboard: Coaches' UV‐related skin cancer knowledge in outdoor sports
von: Sven Schneider, et al.
Veröffentlicht: (2024)

Prevalence of risk factors affecting the use of oral JAK inhibitors in hidradenitis suppurativa
von: Ditte Georgina Zhang, et al.
Veröffentlicht: (2025)

Drugs associated with epidermal necrolysis in children: A World Health Organization pharmacovigilance database analysis
von: Pauline Bataille, et al.
Veröffentlicht: (2024)

BAUSSS biomarker further validated as a key risk staging tool for patients with primary melanoma
von: Anthony J. Dixon, et al.
Veröffentlicht: (2024)

Digital dermoscopy follow‐up for acquired longitudinal melanonychia
von: Elvira Moscarella, et al.
Veröffentlicht: (2025)

Association of dermoscopic signs of regression in melanocytic lesions with immune checkpoint inhibitor response in metastatic melanoma patients
von: Samy Belkaïd, et al.
Veröffentlicht: (2025)

A scoping review of case reports and small case series in Stevens–Johnson syndrome/toxic epidermal necrolysis
von: Mitesh G. Patel, et al.
Veröffentlicht: (2025)

Evaluation of the risk of heart failure with tumour necrosis factor inhibitors: A large‐scale meta‐analysis in immune‐mediated inflammatory diseases
von: Noémi Ágnes Galajda, et al.
Veröffentlicht: (2025)

TNF inhibitors and cardiovascular risk: Friend or foe?
von: Joel M. Gelfand, et al.
Veröffentlicht: (2024)

Reducing cardiovascular risk in immune‐mediated inflammatory diseases: Tumour necrosis factor inhibitors compared to conventional therapies—A systematic review and meta‐analysis
von: N. Á. Galajda, et al.
Veröffentlicht: (2024)

Risk factors for a poor response to propranolol for infantile haemangioma: A prospective study
von: Kaizhi Zhang, et al.
Veröffentlicht: (2025)

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas
von: Damien Sanogo, et al.
Veröffentlicht: (2025)

Association of Janus kinase inhibitors with reduced depression in alopecia areata
von: Chih‐Yi Ho, et al.
Veröffentlicht: (2025)

Correspondence to ‘Cardiovascular and thromboembolic risks of JAK inhibitors in atopic dermatitis’
von: Shiuan‐Chih Chen, et al.
Veröffentlicht: (2025)

Interpreting the risk of venous thromboembolism with JAK inhibitors in atopic dermatitis
von: Sheng Li, et al.
Veröffentlicht: (2025)

Compassionate use efficacy of the interferon‐beta inhibitor dazukibart in dermatomyositis
von: Ruth Ann Vleugels, et al.
Veröffentlicht: (2026)

Combining an anti‐IL‐4Rα biologic with a JAK1 inhibitor leads to a higher treatment response in resistant atopic dermatitis versus monotherapy alone: A case series
von: A. Ferreirinha, et al.
Veröffentlicht: (2024)

Real‐world data on the effectiveness of brodalumab in patients with moderate‐to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study)
von: Dimitrios Rigopoulos, et al.
Veröffentlicht: (2024)

Scratching the surface: NK‐1 inhibitors for chronic itch—Promise or placebo?
von: Gil Yosipovitch
Veröffentlicht: (2025)

Critical methodological enhancements for JAK inhibitor safety studies in atopic dermatitis
von: Zheying Huang, et al.
Veröffentlicht: (2025)

Melanosis and isolated follicular vitiligo during checkpoint inhibitors for metastatic melanoma
von: Valentine Salvestrini, et al.
Veröffentlicht: (2024)

Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
von: Chaofan Wang, et al.
Veröffentlicht: (2025)